These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2048566)

  • 1. Clinical effects of recombinant human interleukin-3.
    Ganser A; Lindemann A; Seipelt G; Ottmann OG; Herrmann F; Eder M; Frisch J; Schulz G; Mertelsmann R; Hoelzer D
    Am J Clin Oncol; 1991; 14 Suppl 1():S51-63. PubMed ID: 2048566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant human interleukin-3 in aplastic anemia.
    Ganser A; Lindemann A; Seipelt G; Ottmann OG; Eder M; Falk S; Herrmann F; Kaltwasser JP; Meusers P; Klausmann M
    Blood; 1990 Oct; 76(7):1287-92. PubMed ID: 2207306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure.
    Ganser A; Lindemann A; Seipelt G; Ottmann OG; Herrmann F; Eder M; Frisch J; Schulz G; Mertelsmann R; Hoelzer D
    Blood; 1990 Aug; 76(4):666-76. PubMed ID: 2383650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes.
    Ganser A; Seipelt G; Lindemann A; Ottmann OG; Falk S; Eder M; Herrmann F; Becher R; Höffken K; Büchner T
    Blood; 1990 Aug; 76(3):455-62. PubMed ID: 2378979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine serum levels during treatment with high-dose recombinant human IL-3 in a patient with severe aplastic anemia.
    Nachbaur D; Gratwohl A; Herold M; Tichelli A; Slanicka M; Nissen C; Niederwieser D; Speck B
    Ann Hematol; 1993 Feb; 66(2):71-5. PubMed ID: 8448242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
    Herrmann F; Mertelsmann R; Lindemann A; Ottmann OG; Seipelt G; Oster W; Hoelzer D; Ganser A
    Biotechnol Ther; 1991; 2(3-4):299-311. PubMed ID: 1845132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human interleukin-3 in patients with hematopoietic failure.
    Ganser A; Lindemann A; Seipelt G; Ottmann OG; Eder M; Herrmann F; Frisch J; Schulz G; Mertelsmann R; Hoelzer D
    Recent Results Cancer Res; 1991; 121():162-72. PubMed ID: 1857856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of phase I/II trials with recombinant human interleukin-3.
    Ganser A; Ottmann OG; Seipelt G; Eder M; Geissler G; Merget R; Maurer A; Falk S; Lindemann A; Herrmann F
    Biotechnol Ther; 1991; 2(3-4):313-25. PubMed ID: 1845133
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia.
    Nimer SD; Paquette RL; Ireland P; Resta D; Young D; Golde DW
    Exp Hematol; 1994 Aug; 22(9):875-80. PubMed ID: 8062886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects on bone marrow during stimulation of hematopoietic stem cells with recombinant human interleukin-3].
    Falk S; Seipelt G; Ganser A; Hoelzer D; Stutte HJ; Hübner K
    Verh Dtsch Ges Pathol; 1990; 74():111-5. PubMed ID: 1708566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic effects of recombinant human interleukin-3 in vivo.
    Lindemann A; Ganser A; Herrmann F; Frisch J; Seipelt G; Schulz G; Hoelzer D; Mertelsmann R
    J Clin Oncol; 1991 Dec; 9(12):2120-7. PubMed ID: 1960553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on hematopoietic regeneration as demonstrated in a nonhuman primate chemotherapy model.
    Winton EF; Srinivasiah J; Kim BK; Hillyer CD; Strobert EA; Orkin JL; Swenson RB; McClure HM; Myers LA; Saral R
    Blood; 1994 Jul; 84(1):65-73. PubMed ID: 8018931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia.
    Farese AM; Herodin F; McKearn JP; Baum C; Burton E; MacVittie TJ
    Blood; 1996 Jan; 87(2):581-91. PubMed ID: 8555480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure.
    Kurzrock R; Talpaz M; Estrov Z; Rosenblum MG; Gutterman JU
    J Clin Oncol; 1991 Jul; 9(7):1241-50. PubMed ID: 2045865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow findings after treatment with recombinant human interleukin-3.
    Falk S; Seipelt G; Ganser A; Ottmann OG; Hoelzer D; Stutte HJ; Hübner K
    Am J Clin Pathol; 1991 Mar; 95(3):355-62. PubMed ID: 1996545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
    Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
    Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential treatment with rmIL-3 or simultaneous treatment with rmIL-3 or rhIL-11 with thrombopoietin (TPO) fails to enhance in vivo neonatal rat thrombocytopoiesis.
    van de Ven C; Fernandez GW; Herbst T; Knoppel A; Cairo MS
    Exp Hematol; 1997 Aug; 25(9):1005-12. PubMed ID: 9257814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study.
    Postmus PE; Gietema JA; Damsma O; Biesma B; Limburg PC; Vellenga E; de Vries EG
    J Clin Oncol; 1992 Jul; 10(7):1131-40. PubMed ID: 1318953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer.
    Biesma B; Willemse PH; Mulder NH; Sleijfer DT; Gietema JA; Mull R; Limburg PC; Bouma J; Vellenga E; de Vries EG
    Blood; 1992 Sep; 80(5):1141-8. PubMed ID: 1515636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.